DATA GRAPHICS | Product Development
The mRNA therapeutics pipeline: Data Byte
At least 21 mRNA-based therapeutics in testing, most of which are for cancer
August 26, 2021 1:28 AM UTC
Having made its mark as a vaccine modality for COVID-19, other mRNA vaccines for infectious diseases are sure to follow. The technology’s potential is much broader than prophylaxis, however. An analysis of active clinical trials listed in ClinicalTrials.gov finds at least 21 mRNA-based therapeutic programs in testing to treat a range of diseases, with cancer by far seeing the most activity.
Of the 21 mRNA therapies, 14 (66%) are designed to treat cancer; these are in testing for at least 10 indications. Moderna Inc. (NASDAQ:MRNA), BioNTech SE (NASDAQ:BNTX) and eTheRNA immunotherapies N.V. are the major players, with eight, five and two cancer mRNA therapies, respectively...